8-K: Delcath Systems Reports Robust 2025, Positive 2026 Outlook

Delcath Systems announced strong financial results for Q4 and full year 2025, with significant revenue growth and positive adjusted EBITDA, alongside an optimistic 2026 outlook.

Summary

• Total revenue for the fourth quarter and full year 2025 was $20.7 million and $85.2 million, respectively.
• HEPZATO KIT revenue for the fourth quarter and full year 2025 was $19.0 million and $78.8 million, respectively.
• CHEMOSAT revenue for the fourth quarter and full year 2025 was $1.7 million and $6.4 million, respectively.
• Gross margins were 85% for the fourth quarter and 86% for the full year 2025.
• Net loss for the fourth quarter was $1.9 million, while full year net income was $2.7 million.
• Non-GAAP positive adjusted EBITDA for the fourth quarter and full year was $2.4 million and $25.1 million, respectively.
• The company repurchased 628,572 common shares for $6.0 million through December 31, 2025, under an approved $25 million Share Buyback Program.
• As of December 31, 2025, the company had approximately $91.0 million of cash and short-term investments and no debt.
• There are currently 28 active treatment centers.
• HEPZATO procedure volume grew approximately 140% in 2025 compared to 2024.
• Additional results from the FOCUS study and results from the Phase 2 CHOPIN trial (CHEMOSAT with ipilimumab and nivolumab) showing significant improvement in one-year progression-free survival were published.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a very positive report, highlighting strong financial performance, significant product adoption, and promising clinical data, positioning the company for continued growth.

Positives

• Achieved significant revenue growth, with full year 2025 total revenue of $85.2 million, up from $37.2 million in 2024.
• Transitioned from a full year net loss of $26.4 million in 2024 to a net income of $2.7 million in 2025.
• Reported strong non-GAAP positive adjusted EBITDA for both Q4 ($2.4 million) and the full year ($25.1 million).
• Maintained a healthy cash and short-term investments balance of $91.0 million with no debt as of December 31, 2025.
• Demonstrated substantial growth in HEPZATO procedure volume, increasing approximately 140% in 2025 compared to 2024.
• Expanded its network to 28 active treatment centers.
• Published positive clinical data from the CHOPIN trial, showing significant improvement in one-year progression-free survival when CHEMOSAT is combined with checkpoint inhibitors.
• Initiated a share buyback program, repurchasing $6.0 million in common shares.

Negatives

• Reported a net loss of $1.9 million for the fourth quarter of 2025, despite achieving full-year net income.
• Research and development expenses increased significantly to $29.2 million in FY25 from $13.9 million in FY24, primarily due to clinical team expansion and new Phase 2 trials.
• Selling, general and administrative expenses rose to $43.5 million in FY25 from $29.6 million in FY24, driven by commercial expansion activities and increased personnel costs.

Risks

• Uncertainties relating to the company's commercialization plans and its ability to successfully commercialize the HEPZATO KIT.
• Challenges in successfully managing the HEPZATO KIT supply chain, including securing adequate supply of critical components necessary for manufacturing and assembly.
• Risks associated with successful FDA inspections of the company's facilities and those of its third-party suppliers/manufacturers.
• The company's ability to successfully implement and manage the HEPZATO KIT Risk Evaluation and Mitigation Strategy (REMS).
• Potential difficulties in obtaining reimbursement for the HEPZATO KIT.
• The company's ability to successfully enter into any necessary purchase and sale agreements with users of the HEPZATO KIT.
• The emergence of new, unpredictable risk factors and uncertainties.

Future Outlook

The company's financial outlook for fiscal year 2026 projects total CHEMOSAT and HEPZATO KIT revenue to be at least $100 million, reflecting an increase in HEPZATO KIT volume of at least 20% over 2025. Gross margins are expected to be in the range of 84% to 87%. Management anticipates accelerated adoption and utilization driven by continued site activations, commercial expansion, and heightened physician awareness of the CHOPIN results.

Management Comments

• "2025 was a pivotal year in which we delivered robust procedure-volume growth, positive operating cashflow and successfully navigated temporary headwinds to stabilize the HEPZATO revenue base in the fourth quarter."
• "With 28 active treatment centers now delivering therapy and compelling CHOPIN data demonstrating clear clinical benefit when PHP is sequenced with checkpoint inhibitors, we enter 2026 with strong momentum."
• "Through continued site activations, commercial expansion, and heightened physician awareness of the CHOPIN results, we expect accelerated adoption and utilization that will drive long-term value for patients and shareholders alike."

Industry Context

StockSavvy.ai notes that Delcath's focus on interventional oncology for liver cancers, particularly metastatic uveal melanoma, positions it in a niche but growing market. The positive CHOPIN trial results, demonstrating improved progression-free survival when PHP is combined with checkpoint inhibitors, could significantly enhance the competitive profile of HEPZATO KIT and CHEMOSAT, potentially expanding their utility beyond monotherapy and aligning with broader oncology trends towards combination therapies.

Comparison to Industry Standards

• The 140% growth in HEPZATO procedure volume in 2025 compared to 2024 is a strong indicator of market penetration and adoption, significantly outpacing typical growth rates for established oncology treatments.
• The gross margins of 85% for Q4 and 86% for the full year are exceptionally high for a medical device/drug combination product, suggesting strong pricing power and efficient manufacturing, potentially outperforming many peers in the specialized oncology sector.
• The transition from a significant net loss in 2024 to net income in 2025, alongside positive adjusted EBITDA, demonstrates a strong operational turnaround and financial discipline, which is a positive outlier compared to many development-stage or early commercial-stage biotech companies.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, share buyback, and optimistic future guidance, potentially leading to increased share value.
• Patients: Positive impact through increased access to HEPZATO KIT via more active treatment centers and promising clinical data for combination therapies, offering improved treatment options for liver cancers.
• Employees: Positive impact due to company growth, commercial expansion, and clinical team expansion, potentially leading to job security and growth opportunities.

Next Steps

• Continued site activations for HEPZATO KIT.
• Commercial expansion efforts.
• Heightened physician awareness campaigns regarding CHOPIN results.
• Initiation of Phase 2 clinical trial evaluating HEPZATO in combination with standard of care for mCRC and mBC.
• Ongoing share buyback program.

Key Dates

Recommendation

The company has demonstrated a significant turnaround, achieving full-year net income and strong adjusted EBITDA. The 140% growth in HEPZATO procedure volume and the positive 2026 revenue guidance of at least $100 million indicate robust commercial momentum. The strong cash position and share buyback program further enhance shareholder value. Promising clinical data from the CHOPIN trial suggests potential for expanded market opportunities. These factors collectively point to strong future growth and profitability, making it a compelling investment.

Keywords

Delcath Systems, DCTH, interventional oncology, liver cancer, HEPZATO KIT, CHEMOSAT, melphalan, uveal melanoma, metastatic cancer, financial results, adjusted EBITDA, share buyback, clinical trials, CHOPIN study, FDA approval